PLENARY 1



Parag Nimbolkar Medicines Patent Pool (MPP)

"Landscape analysis of approvals and market update of generic or equivalent formulations for CNS LAI medicines"

"[CNS-focused LAIs] are more commercially successful ... the idea is to collaborate and understand their journey of development"

Market analysis of CNS-focused products Summary of EMA/FDA approvals of LAI products.




Takeaways.

- Huge delays from brand to generic and 505(b)(2) product approvals. Risperidone LAI
 - 15 years to first 505(b)(2) product approval: Perseris (Indivior). * Nearly 20 years to first generic product approval: grisperidone (TEVA).
 - ◊ Paliperidone LAI.
 - 12 years to first 505(b)(2) and generic product approvals.
- Few therapeutically equivalent products vs 505(b)(2) products.
- Recent uptick in generic development and approvals due to improved clarity of regulatory guidance.
 - More companies are devoting resources to creating their own technology platform,
 - "cracking" formulation complexity, and developing a therapeutically equivalent product.
- Risperidone LAI. Generic developers have made huge strides in recent years
- Paliperidone palmitate LAI. At least five generic companies with tentative approvals
- Most generic products are not present in LMICs. In Generics are in Australia, Canada, Europe, Japan, and US.

Impact of generic entry. Generally, prices decrease with benefit to

the consumer. Risperidone LAI pricing analysis. Generic (Yellow)/alternative product (Blue) launch impacts pricing and innovator (Gold) sales; Degree of impact varies by territory.



Generics are capturing the market very fast, at least starting with high-income countries. * Innovator market share decreased from 91% in 2021 to 74% by the end of 2023.

Paliperidone palmitate pricing analysis. Impact of generic/alternative product launch on pricing will be visible in a few years

India – Huge difference in price between the

Generics have only recently been launched. ٥ China - Generic launched at a huge discount & will impact innovator (Gold) price in 2024.



Noteworthy success stories

Aristada (Aripiprazole lauroxil) IM ER suspension.

- Submission type. Type 1 new molecular entity.
- Technology: Nanocrystal technology. RLD: Abilify tablets.
- Clinical path. Alkermes submitted P3 (safety and efficacy) and SD/MD P1 PK studies. Prior agency finding of safety and efficacy for oral aripiprazole was considered.
- Value addition. First LA atypical antipsychotic with QM and Q6W dosing options.
- Commercial performance. Doing well against the innovator. \$444M in sales vs Innovator \$1.2B (2023)

Rytary (Carbidopa and Levodopa) ER capsule.

- Submission type. Type 5 new formulation or new manufacturer Technology: IR and ER beads designed for different release rates in GI tract. RLD: Sinemet tablet, Sinemet CR tablet, and Stalevo tablet.
- Clinical path. Impax submitted two randomized P3 studies and six additional studies (i.e., PK, food effect, BA)
- Value addition.
 - Consistent PK profile to reduce motor fluctuations and dosing frequency.
 - Reduced time interval where patient symptoms are inadequately controlled.
- ER formulation improves "off time" by over one hour each day. Commercial performance. Captured the market.
- \$298M in sales vs Innovator NA (2023) ۵

Cinvanti (Aprepitant) IV emulsion.

- - Submission type. Type 3 new dosage form. Technology. Oil-in-water emulsion with improved aprepitant solubility. RLD: Emend (fosaprepitant) injection.
 - Clinical Path. Heron Therapeutics submitted two BA studies.
- Value addition.
 - Unique synthetic, surfactant-free formulation administered as IV push or infusion. IV push saves \$1.99 per push and 33 min vs 30-min IV infusion.
- Commercial performance. Captured the market; \$187M in sales vs Innovator \$9M (2023)

Sublocade (Buprenorphine) SC ER injection.

- Submission type. Type 3 new dosage form. Technology. Atrigel technology (in situ-forming gel/depot for SR over one month).
- RLD: Subutex SL tablet Clinical Path. Indivior submitted one inpatient opioid blockade study and one RCT for safety and efficacy
- Value addition.
 - Sustains therapeutic plasma concentrations for one month. Blocks rewarding affects of opioids.
 - Commercial performance. Captured the market.
- \$192M in sales vs Innovator withdrawn (2023) ٥